Wegovy and Water Retention: What Really Happens on the Scales

What the STEP trial data actually recorded about fluid and weight changes

The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity for 68 weeks on semaglutide 2.4mg alongside lifestyle changes. The headline finding was around 15% average body-weight reduction, but the trial also captured changes in body composition. Lean mass (including the water held within muscle) fell alongside fat mass, which is the standard pattern for calorie-restricted weight loss at scale.

This matters because the body stores roughly 3 grams of water for every gram of glycogen. When food intake drops sharply, glycogen depletes fast, and a noticeable volume of water goes with it. That is partly why the first weeks on Wegovy often produce a larger number on the scales than the fat loss alone would explain. It is also why some people feel lighter, less bloated and less puffy quite quickly after starting. The effect is real and measurable, it just is not the same as losing body fat.

What the trial did not find was a consistent pattern of oedema (the medical term for fluid accumulating in tissue) as a common adverse event. Oedema features in the Wegovy SmPC as an uncommon effect. The distinction between normal early fluid shifts and true water retention is clinically important, and the NHS guidance on semaglutide lists the side effects patients and clinicians should monitor.

Why the scales sometimes go the other way, and what triggers it

A subset of people do report feeling more puffy or retaining fluid at certain points during treatment. The most consistent pattern is around dose increases. As the prescriber steps up from one strength to the next, GI side effects like nausea and reduced appetite often intensify briefly. The body's fluid regulation is sensitive to changes in sodium intake, carbohydrate intake and overall eating pattern, all of which shift when appetite suppression deepens.

Reduced drinking is a quieter contributor. Wegovy affects how much patients want to eat and drink, and lower fluid intake can paradoxically encourage the body to hold onto the water it has. Staying well hydrated is a practical step that matters more during treatment than many people realise.

Hormonal and physiological factors layer on top. If someone is also using HRT or hormonal contraception, both of which can affect fluid balance independently, the picture becomes harder to read. None of this should be managed by self-adjustment. The right approach is to flag changes to your prescriber, who can assess whether what you are experiencing is an expected shift or something that needs investigation.

There is also the straightforward calendar effect worth naming: if a monthly order arrives just before a holiday or a long weekend, or if payday timing means a gap between doses, any break in treatment can reset the body's fluid balance in either direction. Consistency of dosing matters.

When to treat fluid changes as a reason to seek medical help

Most fluid shifts on Wegovy resolve without any intervention. But some symptoms should not be attributed to treatment without a clinician's assessment. Significant swelling in the legs, ankles or feet, facial puffiness that persists beyond a few days, or sudden unexplained weight gain (a kilogram or more in 24 hours) each deserve a conversation with a doctor or pharmacist the same day, not a wait-and-see approach.

Semaglutide can cause gastrointestinal side effects that lead to dehydration (particularly vomiting or diarrhoea) and paradoxically the body's response to dehydration can include holding fluid in certain compartments. If you are managing significant nausea or gut symptoms and also noticing unusual swelling, those two things together are worth reporting. The MHRA's Yellow Card scheme exists precisely so that patterns like this are captured at a population level, not just addressed one patient at a time.

People with pre-existing heart, kidney or liver conditions that already affect fluid retention require especially careful monitoring during GLP-1 treatment. A good prescribing service will have reviewed these as part of eligibility assessment. That kind of structured clinical oversight, where a prescriber reads your answers and history before treatment starts and again at each review, is what distinguishes a safe treatment pathway from simply receiving medication in the post.

Putting it together: how to think about water weight during treatment

Wegovy and water retention, in clinical terms, is mostly a story about fluid loss rather than fluid gain. Early weight changes on the scales are often faster than fat loss alone would produce because glycogen and its associated water leave quickly when appetite falls. Dose-increase periods can bring temporary puffiness. Hydration matters more than most people on treatment realise. And persistent or significant swelling is not a side effect to normalise.

For a fuller look at how semaglutide interacts with hydration habits day to day, the guidance on water intake during Wegovy treatment covers practical steps in detail. The broader question of what water weight specifically is and how it differs from fat loss is unpacked on the water weight and Wegovy page. If you are weighing up whether semaglutide is the right choice for your situation, the full Wegovy overview and a detailed look at semaglutide as the active medicine behind it both offer more context. Questions about semaglutide and fluid balance in general are explored further on the semaglutide and water page.

If you have more specific clinical questions, speaking to a prescriber is the right step. Our clinical team reviews every patient consultation personally. Speak to our prescribers to start a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber.